ADVERTISEMENT
ADVERTISEMENT

PD-1 Inhibitor Screening Assay Kit

AMSBIO has announced a new PD-1 (Programmed Death) inhibitor screening assay kit.

AMSbio

AMSBIO has announced a new PD-1 (Programmed Death) inhibitor screening assay kit for cancer research studies.

Immunotherapy for the treatment of cancer is rapidly evolving from therapies that globally and non-specifically simulate the immune system to more targeted activation of individual components of the immune system. The net result of this targeted approach is decreased toxicity and increased efficacy of immunotherapy. The understanding of the checkpoint signalling pathway involving the programmed death 1 (PD-1) receptor and its ligands (PD-L1/2) in tumour-induced immune suppression has been a critical advancement in immunotherapeutic drug development.

Cell signalling through the PD-1 receptor upon binding the PD-L1 ligand attenuates immune responses and is exploited by both tumours and viruses. The PD-L1 Inhibitor Screening Assay Kit from AMSBIO is designed for screening and profiling inhibitors of this signalling. This kit comes in a convenient 96-well format, with biotin-labelled PD-1, purified PD-L1 or PD-L2, streptavidin labelled HRP,...

AMSBIO offers many purified, soluble immunoreceptors involved in key immunosignalling pathways. Additionally, the company offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective. Custom services include stable cell line production, CRISPR/Cas9 Genome Editing, lentivirus and adenovirus production, large scale protein production and a comprehensive portfolio of antibody services.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT